Orion develops new pharmaceuticals in three therapy areas. Orion’s pharmaceutical R&D focuses on the neurological diseases and oncology, and inhalable pulmonary drugs. Orion also develops veterinary and generic drugs.
The Neurological Disorders Research aims to discover new drugs for the treatment of neurological diseases including rare neurological diseases. The main research focus areas include mechanisms of pain and proteinopathies.
Medicinal substances for the treatment of Parkinson’s disease have long been focus areas of Orion’s R&D. Orion’s most successful proprietary drugs, Comtess® and Stalevo®, are the result of these research projects.
Orion oncology develops novel proprietary drugs for the treatment of cancer. Orion’s oncology research and development has a long history with top expert professionals in the field. The first proprietary drug, Fareston®, has been on market for breast cancer already since 1988.
While endocrine regulated cancers continue to be an important focus for Orion cancer research, Orion has expanded its research activities to include also mechanisms driving cancer, including mechanisms of immuno-oncology.
Easyhaler® is an environmentally friendly and easy-to-use inhaler (dry powder inhaler) developed and patented by Orion. Orion aims to expand the product family of inhalable drugs used for treating asthma and chronic obstructive pulmonary disease.
Easyhaler® technology can also be used in the R&D of new proprietary drugs.
Orion’s veterinary product development has a long history in the microbiome based treatments. In addition, our human drug and formulation innovations are utilised when new therapies and treatment methods are being developed for animals.
To balance its operations, Orion simultaneously develops and co-develops several new generic medicinal substances in collaboration with its partners. A generic drug is a drug that contains the same active pharmaceutical ingredient as a corresponding proprietary product that no longer has patent protection.
The development of generic drugs is more simple and economical than the development of proprietary drugs since the necessary studies on the active ingredient have already been carried out.
The development of generics usually takes two to three years.
“If you manage to develop even one good cancer drug that is effective and well tolerated, it will have an earth-shattering global impact. This is a goal that is worth working towards,” says Joensuu.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug discovery and development.